Clinical Trials Directory

Trials / Completed

CompletedNCT01913964

Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
Sponsor
University of Catania · Academic / Other
Sex
All
Age
45 Years – 65 Years
Healthy volunteers
Accepted

Summary

To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.

Conditions

Interventions

TypeNameDescription
DRUGAcetylcarnitine
DRUGPlacebo(sugar pill)

Timeline

Start date
1997-10-01
Primary completion
1997-10-01
Completion
1997-10-01
First posted
2013-08-01
Last updated
2013-08-01

Source: ClinicalTrials.gov record NCT01913964. Inclusion in this directory is not an endorsement.

Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin (NCT01913964) · Clinical Trials Directory